ID | 32881 |
JaLCDOI | |
フルテキストURL | |
著者 |
Murakami, Takanori
Himeji St. Mary’s Hospital
Ebara, Shin
Okayama University
Saika, Takashi
Okayama University
Irie, Shin
Okayama Central Hospital
Takeda, Katsuji
Kagawa Prefectual Hospital
Maki, Yoshio
Konko Hospital
Miyaji, Sadayuki
Kawasaki Medical School Hospital
Manabe, Daisuke
Kagawa Prefectual Hospital
Tsushima, Tomoyasu
National Okayama Hospital
|
抄録 | We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology./ |
キーワード | bladder cancer
BCG therapy
transurethral biopsy
cystoscopy
urinary cytology
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2007-12
|
巻 | 61巻
|
号 | 6号
|
出版者 | Okayama University Medical School
|
開始ページ | 341
|
終了ページ | 344
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID |